Which is Better for Weight Loss: Wegovy or Mounjaro?

Last reviewed: June 18, 2026

Last updated: June 18, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

Both Wegovy (semaglutide) and Mounjaro (tirzepatide) have demonstrated significant weight loss results in clinical trials, with participants losing 15% to 22% of body weight over one year. However, these medications work through different pathways in the body, and individual response varies considerably based on genetics and metabolism. Choosing between them—or exploring compounded alternatives—requires understanding their distinct mechanisms and how your unique peptide profile responds to each approach.

How Wegovy Works for Weight Loss

Wegovy contains semaglutide, a GLP-1 receptor agonist that mimics glucagon-like peptide-1, a hormone controlling hunger and blood sugar. The medication activates receptors in the brain's satiety centers, reducing appetite and food intake while slowing gastric emptying to prolong fullness. Clinical trials showed participants lost an average of 15% of body weight, with some achieving up to 18% reduction over 68 weeks.

Semaglutide also improves insulin sensitivity and reduces caloric intake by approximately 340 calories per day on average. The medication is administered as a weekly injection, with doses escalating from 0.25 mg to a maximum of 2.4 mg. Response typically becomes noticeable within 2 to 4 weeks, though maximum results often take 16 to 20 weeks to manifest fully.

Understanding Mounjaro's Dual-Pathway Mechanism

Mounjaro (tirzepatide) activates both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors, making it a dual-action medication. By targeting two appetite-regulating pathways instead of one, tirzepatide produces more robust hunger suppression and greater metabolic effects than single-pathway agents. The SURMOUNT trials demonstrated that tirzepatide achieved weight loss of 20% to 22% of body weight—approximately 5% greater than semaglutide alone.

The dual mechanism also enhances insulin secretion and improves cardiovascular markers more effectively than GLP-1 monotherapy. Tirzepatide requires weekly injections and doses range from 2.5 mg to 15 mg, with most patients achieving optimal results at 10 mg or 15 mg weekly. The medication's broader pharmacological footprint makes it particularly effective for individuals whose genetic profile predisposes them to stronger GIP pathway activation.

Key Differences in Weight Loss Outcomes

Head-to-head comparison studies demonstrate that tirzepatide consistently outperforms semaglutide, with participants losing approximately 2 to 4 additional percentage points of body weight. However, 'better' depends on individual factors: some patients respond equally well to either medication, while others show markedly superior results with the dual-action approach. The difference becomes most pronounced in individuals with baseline BMI above 35 or those with family histories of type 2 diabetes.

Cost-effectiveness differs significantly between the two. Wegovy carries a manufacturer price of approximately $1,349 per month, while Mounjaro ranges from $1,041 to $1,349 depending on dosage tier. Insurance coverage remains inconsistent for both, often requiring prior authorization or documentation of weight-related comorbidities. Neither medication produces permanent weight loss; discontinuation typically results in gradual weight regain over 6 to 12 months.

Why Genetic Testing Reveals Your Optimal GLP-1 Match

Not every patient responds equally to semaglutide or tirzepatide because genetic variations influence peptide receptor sensitivity and metabolic pathways. The GLP1R rs6923761 variant, for example, affects how efficiently your cells respond to GLP-1 signaling, while the GIPR rs1800437 variant determines your capacity to activate the GIP pathway. PlexusDx Precision Peptide Genetic Test identifies these and 12 additional genetic markers across 14 metabolic pathways, predicting your individual response profile before starting treatment.

Individuals carrying certain variants may experience stronger appetite suppression from tirzepatide's dual action or show equal effectiveness with semaglutide at lower doses. The FTO rs9939609 variant influences overall fat accumulation risk and predicts sustained weight loss maintenance potential. Testing costs $99 as an add-on after your first month of treatment and informs whether you'll achieve better results with a dual-compound approach like GLP-Squared or remain optimized on single-agent therapy.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Tirzepatide Injection starts at $249/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Is tirzepatide (Mounjaro) actually more effective than semaglutide (Wegovy) for weight loss?

Clinical data shows tirzepatide produces approximately 20% to 22% body weight loss versus 15% to 18% with semaglutide, representing a meaningful but not universal difference. Individual response varies significantly based on genetics, baseline metabolic health, and adherence. PlexusDx genetic testing identifies which mechanism (single GLP-1 vs. dual GLP-1/GIP) aligns with your peptide pathways.

What are the main side effects of each medication?

Both semaglutide and tirzepatide commonly cause nausea, vomiting, constipation, and diarrhea, especially during dose escalation. Tirzepatide users report slightly higher rates of gastrointestinal side effects but often at lower intensity per unit of weight loss achieved. Serious adverse events remain rare; most side effects resolve within weeks as the body adapts.

Can I switch from Wegovy to Mounjaro or try both?

Switching from semaglutide to tirzepatide is medically feasible and typically involves a washout period of 1 to 2 weeks before starting the new medication. PlexusDx offers GLP-Squared Injection, which combines compounded semaglutide and tirzepatide in one formulation, allowing dual-pathway activation without separate injections. This approach can optimize results for patients who benefit from both mechanisms.

How does PlexusDx compounded tirzepatide compare to brand-name Mounjaro?

PlexusDx compounded tirzepatide injection contains identical active pharmaceutical ingredients and is manufactured by licensed 503A compounding pharmacies under the same quality standards. Compounded versions cost $249 to $289 monthly depending on commitment tier, whereas brand Mounjaro typically costs $1,041 to $1,349 without insurance. Both require weekly injection and produce equivalent clinical results.

What does the Precision Peptide Genetic Test actually measure?

The test analyzes genetic variants in GLP1R, GIPR, FTO, and MC4R genes along with 10 additional metabolic markers, mapping 49 peptides across 14 pathways to predict your medication response profile. It is a peptide-pathway genetic test—not a pharmacogenomic test—designed specifically to identify whether you'll respond optimally to GLP-1 monotherapy, GIP agonists, dual-action medications, or microdose protocols. Results guide PlexusDx treatment selection for maximum weight loss and sustainability.

Related Reading

• Wegovy For Weight Loss 2
• Mounjaro For Weight Loss 2
• Wegovy Weight Loss Pills
• Weight Loss Mounjaro

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.